Milestone Pharmaceuticals has announced that a Phase 1 clinical trial of an intranasal formulation of its MSP-2017 calcium channel antagonist for possible treatment of paroxysmal supraventricular tachycardia (PSVT) showed that the drug has a rapid onset, along with other promising PK properties, and was well tolerated at doses up to 140 mg. The company said that it plans to conduct a Phase 2 trial in patients with PSVT beginning in the first half of 2015.
Milestone VP of Drug Development Douglas Wight said, “The results supported the selection of one of the formulations for subsequent clinical development in the Phase 2 proof-of-concept study. The rapid absorption of MSP-2017 into the central compartment following nasal delivery is ideal for an immediate treatment of PSVT episodes.”
Chief Medical Advisor Philip Sager added, “We are pleased with the safety profile of MSP-2017 in this Phase 1 study. We did not observe QT prolongation, AV block, or significant hypotension up to the maximal feasible dose. This Phase 1 study validates the product concept because a prolongation of the PR interval as measured by ECG is associated with modulation of the atrio-ventricular (AV) node in the heart, which underlies the pathology in PSVT. MSP-2017 is being developed as a self-administered episodic treatment for acute PSVT.”
Read the Milestone press release.
